We are live on ! Find out more
CC

Casdin Capital Portfolio holdings

AUM $2B
1-Year Est. Return 147.21%
This Fund
S&P 500
This Quarter Est. Return
+21.79%
1 Year Est. Return
+147.21%
3 Year Est. Return
+369.71%
5 Year Est. Return
+164.99%
10 Year Est. Return
+6,568.53%
AUM
$569M
AUM Growth
+$158M
Cap. Flow
+$82.7M
Cap. Flow %
14.55%
Top 10 Hldgs %
57.69%
Holding
35
New
8
Increased
13
Reduced
–
Closed
4

Top Buys

Rank Stock Value
1
IBB icon
iShares Biotechnology ETF
IBB
+$10.5M
2
ONCE
Spark Therapeutics, Inc. Common Stock
ONCE
+$9.27M
3
ONC
BeOne Medicines Ltd
ONC
+$7.04M
4
ILMN icon
Illumina
ILMN
+$6.48M
5
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$6.45M

Top Sells

Rank Stock Value
1
SYRS
Syros Pharmaceuticals, Inc. Common Stock
SYRS
+$2.67M
2
GILD icon
Gilead Sciences
GILD
+$2.15M
3
OVID icon
Ovid Therapeutics
OVID
+$1.58M

Sector Composition

Rank Sector Weight
1 Healthcare 97.59%
2 Miscellaneous 2.41%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LOXO
1
DELISTED
Loxo Oncology, Inc
LOXO
$41.5M 7.3%
360,000
– –
FMI
2
DELISTED
Foundation Medicine, Inc.
FMI
$41M 7.2%
520,000
– –
SAGE
3
DELISTED
Sage Therapeutics
SAGE
$40.3M 7.08%
250,000
– –
BPMC
4
DELISTED
Blueprint Medicines
BPMC
$31.9M 5.61%
348,000
– –
ONCE
5
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
$30.8M 5.42%
463,000
+160,526
+53% +$9.27M
AGIO icon
6
Agios Pharmaceuticals
AGIO
$2.01B
$29.8M 5.25%
364,776
+69,776
+24% +$5.39M
ALNY icon
7
Alnylam Pharmaceuticals
ALNY
$32.9B
$29.8M 5.24%
250,000
+50,000
+25% +$6.45M
GBT
8
DELISTED
Global Blood Therapeutics, Inc.
GBT
$29M 5.1%
600,000
+85,000
+17% +$4.74M
MYOK
9
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$27.3M 4.81%
560,000
– –
SGMO
10
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$26.6M 4.68%
1,400,000
– –
FATE icon
11
Fate Therapeutics
FATE
$302M
$25.4M 4.46%
2,600,000
– –
BLUE
12
DELISTED
bluebird bio
BLUE
$24.8M 4.35%
11,194
– –
CDXS icon
13
Codexis
CDXS
$145M
$22.3M 3.92%
2,025,000
+425,000
+27% +$4.07M
VYGR icon
14
Voyager Therapeutics
VYGR
$187M
$21.3M 3.75%
1,135,000
– –
GNMK
15
DELISTED
GenMark Diagnostics, Inc
GNMK
$20.9M 3.68%
3,850,000
+1,120,000
+41% +$5.57M
ILMN icon
16
Illumina
ILMN
$37B
$16.9M 2.97%
73,502
+28,270
+63% +$6.48M
EVH icon
17
Evolent Health
EVH
$415M
$15.8M 2.78%
1,110,000
+32,500
+3% +$465K
JNCE
18
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
$14.2M 2.5%
635,000
+160,000
+34% +$3.55M
BOLD
19
DELISTED
Audentes Therapeutics, Inc
BOLD
$13.5M 2.38%
450,000
+50,000
+13% +$1.69M
ONC
20
BeOne Medicines Ltd
ONC
$40B
$11.8M 2.07%
70,000
+52,000
+289% +$7.04M
IBB icon
21
iShares Biotechnology ETF
IBB
$10.5B
$10.1M 1.78%
+95,000
New +$10.5M
CLVS
22
DELISTED
Clovis Oncology, Inc.
CLVS
$9.37M 1.65%
177,500
+50,000
+39% +$2.92M
CRSP icon
23
CRISPR Therapeutics
CRSP
$5.54B
$6.17M 1.09%
+135,000
New +$5.57M
CTMX icon
24
CytomX Therapeutics
CTMX
$614M
$5.9M 1.04%
207,500
+30,000
+17% +$856K
EDIT icon
25
Editas Medicine
EDIT
$418M
$4.42M 0.78%
133,333
– –
1
2

Similar funds

KOCAA
Knights of Columbus Asset Advisors New Haven, Connecticut $2B AUM 42.86% 1-Year Est. Return
NL
NWAM LLC Mercer Island, Washington $2B AUM 34.81% 1-Year Est. Return
CAM
Cacti Asset Management Atlanta, Georgia $1.99B AUM 86.33% 1-Year Est. Return
SB
Strategic Blueprint Atlanta, Georgia $2B AUM 27.02% 1-Year Est. Return
BGGS
Boussard & Gavaudan Gestion SAS Paris, France $1.99B AUM
CC
Courier Capital Buffalo, New York $2B AUM 24.36% 1-Year Est. Return
JWA
JFS Wealth Advisors Hermitage, Pennsylvania $2.01B AUM 21.74% 1-Year Est. Return
FOF
Fenelon Opportunity Fund Dallas, Texas $2.01B AUM

Casdin Capital's Q1 2018 Portfolio in Review

As of Q1 2018, Casdin Capital held 35 positions worth $569M, up 38% from $411M the previous quarter. Its ten largest holdings account for 58% of the portfolio.

Casdin Capital deployed $82.7M of net new capital in Q1 2018, opening 8 new positions and adding to 13 existing holdings. Its largest new stake was iShares Biotechnology ETF: 95,000 shares worth $10.1M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 100% a quarter earlier, followed by Miscellaneous.

On the sell side, the most notable exit was Syros Pharmaceuticals, Inc. Common Stock, an estimated $2.67M sold.

  • Casdin Capital's largest Q1 2018 buy was iShares Biotechnology ETF: 95,000 shares worth $10.1M.
  • Casdin Capital added most to Spark Therapeutics, Inc. Common Stock in Q1 2018, an estimated $9.27M increase.
  • Casdin Capital fully exited Syros Pharmaceuticals, Inc. Common Stock in Q1 2018, selling an estimated $2.67M.
  • Casdin Capital's ten largest holdings make up 58% of its $569M portfolio in Q1 2018.
  • Casdin Capital opened 8 new positions and closed 4 in Q1 2018.
  • Casdin Capital's portfolio value rose 38% quarter-over-quarter to $569M.

Based on Casdin Capital's 13F filing for Q1 2018, filed 15 May 2018.